NeuBase Therapeutics, Inc.-Sarasota Dinner

1111 Ritz Carlton Drive,Sarasota FL 34236

27 January, 2022

Description

NeuBase Therapeutics, Inc. (NASDAQ: NBSE) Lunch Presentation-Please register to attend the event *Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Bear Creek Capital Presents:Dinner & Corporate PresentationNeuBase Therapeutics, Inc.  (NASDAQ:  NBSE)Thursday, January 27, 2022The Ritz Carlton1111 Ritz Carlton DriveSarasota, FL 34236Promptly at 6:00 PMJoin Neubase Therapeutics, Inc. Chairman and CEO, Dr. Dietrich Stephan, Ph.D for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. We hope you can join our presentation About NeuBase Therapeutics, Inc.NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders. In the NewsNeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021 NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology OfficerNeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer Presentation Format:  6:00 p.m. to 7:30 p.m. – Presentation and Lunch Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]